In 2004, Nigeria was admitted into the WHO International Drug Monitoring Scheme as its 74th member after initial pharmacovigilance (PV) activities in a number of locations in the country. Its PV system is based on voluntary spontaneous reporting of adverse drug reactions. The operating system is the Vigiflow linked to the Uppsala Monitoring Centre and currently holds > 10,000 ICSRs in its local database. The country has recently set up a zonal (regional) PV structure with 6 centers, in consonance with its geopolitical set-up, which are linked to the National Pharmacovigilance Centre in the capital city Abuja. A PV policy document has just been launched to guide PV activities in the country.
The main thrust of the PV activities is the sensitization of the general population and health care providers to raise the level of awareness, as well as further advocacy of supervising regulatory bodies to ensure improved role of professionals and other stakeholders in PV. The current challenges include the engagement of the pharmaceutical industries, local and international, and the practitioners in herbal medicine. Again, coverage of the pediatric and geriatric population has also come into view.
In all, PV has made tremendous progress in Nigeria in the decade since its membership in the WHO international monitoring network. Most medicines in Europe are not authorized for use in children: almost 50% of medicines prescribed to children in the hospital are unlicensed for their age group or prescribed off-label. There are major practical and ethical issues in relation to studying medicines in children, especially in neonates. To improve the situation, a pediatric regulation entered into force in 2007, and the European Medicines Agency identified drugs as priority medicinal products for evaluation in children. The TINN project was selected by the FP7 program to evaluate ciprofloxacin and fluconazole. It was launched in 2008, and data evaluating ciprofloxacin are presented. Ciprofloxacin is a fluoroquinolone for the treatment of multiresistant gram-negative bacterial sepsis with an acceptable safety profile and a useful pattern of bacterial susceptibility. The TINN project included: (1) a literature review on ciprofloxacin in pediatric patients 2 ; (2) juvenile animal studies using Phenopus 3 ; and (3) a survey in Europe included 193 NICUs from 32 countries. (4) Results showed that ciprofloxacin is used in 25% of NICUs, but indications and dosages vary widely 4 ; a ciprofloxacin method was developed in low sample volumes 5 ; (5) a population pharmacokinetic study (Liverpool, United Kingdom and Paris, France) included 51 neonates, showing that ciprofloxacin clearance was dependent on current weight, gestational and postnatal age, and renal function and that volume of distribution was dependent of current weight 6 . A PIP for ciprofloxacin was not validated and no Paediatric-Use Marketing Authorisation (PUMA) will be obtained because the studies required were not possible to perform and the market is too small to expect viability of a new formulation. However, the studies conducted within TINN allow dosage recommendations to treat suspected or proven resistant gram-negative infections.
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